KBI Biopharma
Presentation | Platform Techniques for Preformulation Development for Non-Antibody Products
Presentation | Platform Techniques for Preformulation Development for Non-Antibody Products
At KBI Biopharma, our PUREplatform™ is everything you need to make a protein. Catered to your needs, our service package contains plasmids, strains, media, and a fermentation process that fit perfectly and efficiently together. Learn more about how to easily jump-start your microbial program to reduce impurities and reach higher titers.
An ideal therapeutic protein “factory” creates a pure target product with high titers from the start, which can minimize development risk, timelines, and cost. E. coli has long been implemented as a therapeutic protein factory due to its simplicity, tractability, and wealth of information characterizing the microbe.
While common E. coli expression strains alter as many as five genes to improve one aspect of recombinant protein expression, KBI has created a platform E. coli with about 1,000 genes altered and roughly 1 Mbp of DNA removed. The result is a PURE, efficient platform expression strain—PUREcoli™.
PUREcoli™
PURE in. PURE out.
Fill out the Form Below to Download the Whitepaper:
Presentation | Primary Recovery & Harvest Processes for non-mAb Recombinant Proteins
Presentation | Primary Recovery & Harvest Processes for non-mAb Recombinant Proteins
.png)
BIOSECURE, Tariffs, and the New CDMO Reality for Biopharma Innovators
KBI Biopharma : May 27, 2026, 8:00:03 AM
Biopharma innovators must rethink CDMO strategies amid new tariffs and the BIOSECURE Act, focusing on long-term defensibility and supplier risk.